Modern CEO Stephane Bancel discusses company earnings and cost-cutting benefits in response to Covid business decline. Topics include balancing cost efficiency with innovation, progress on a melanoma vaccine, potential accelerated approval, and the impact of AI on drug production and clinical development.
Moderna focuses on cost-cutting and innovation to drive sales and research.
Artificial intelligence accelerates drug discovery and process optimization at Moderna.
Deep dives
Moderna's Cost-Cutting Strategy and R&D Focus
Moderna CEO Stefan Bansell discusses the balance between cost-cutting and innovation, highlighting the company's emphasis on driving sales and research. The company has strategically prioritized investments, such as in respiratory vaccines, where phase three studies help reduce costs. Additionally, partnerships like the one with Merck allow for shared expenses, enhancing efficiency in research and development. Bansell emphasizes the importance of technology, including AI, in scaling the company and increasing productivity across various areas like manufacturing and commercial operations.
Utilizing AI for Accelerated Drug Development
Stefan Bansell underscores the role of artificial intelligence in speeding up drug production and understanding biological processes. AI aids in expediting the discovery of new drugs by enhancing the comprehension of disease biology. At Moderna, AI is already streamlining processes, such as dose selection during clinical studies, significantly reducing the time required for decision-making. By applying AI to various facets of drug development, including data analysis and communication with regulators, Bansell anticipates significant time savings and increased efficiency in bringing new drugs to market.
Moderna CEO Stephane Bancel discusses company earnings and the benefits of cost-cutting to offset their Covid business decline. He speaks with Bloomberg's Jonathan Ferro and Lisa Abramowicz.